<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>阿斯利康最好的COVID疫苗结果是fl幸。专家有疑问AstraZeneca’s best COVID vaccine result was a fluke. Experts have questions</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">AstraZeneca’s best COVID vaccine result was a fluke. Experts have questions<br/>阿斯利康最好的COVID疫苗结果是fl幸。专家有疑问</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-11-26 06:30:52</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/11/4456753d139ecb111492fd59877b7e3f.jpg"><img src="http://img2.diglog.com/img/2020/11/4456753d139ecb111492fd59877b7e3f.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Pharmaceutical giant AstraZeneca and the University of Oxford made a n exciting announcement Monday: the COVID-19 vaccine they developed together appeared up to 90 percent effective at preventing disease. But in the days since, that exciting news melted into a pool of confusion after it became clear that the 90 percent figure came about from a complete accident. Now, experts are scratching their heads over what actually happened in the trial and what it means for the vaccine’s future.</p><p>制药业巨头阿斯利康和牛津大学周一发表了令人振奋的公告：他们共同开发的COVID-19疫苗在预防疾病方面显示出高达90％的有效率。但是在那之后的几天里，令人兴奋的消息变得一团糟，因为很明显90％的数字来自一次完全的事故。现在，专家们在试验中实际发生的事情以及对疫苗的未来意味着什么的问题上scratch之以鼻。</p><p> The questions all swirl around the vaccine’s dosage regimen. In initial press releases, AstraZeneca and Oxford explained that researchers had used two different dosage regimens to test their experimental vaccine, AZD1222. In one regimen, trial participants received two “full” vaccine doses, 28 days apart. In the other, participants received a half dose of vaccine followed by a full dose 28 days later.</p><p> 所有这些问题都围绕着疫苗的剂量方案。在最初的新闻稿中，阿斯利康和牛津大学解释说，研究人员使用了两种不同的剂量方案来测试他们的实验疫苗AZD1222。在一种方案中，试验参与者接受了两次“全”疫苗剂量，相隔28天。在另一种情况下，参与者接受了半剂量的疫苗，然后在28天后接受了全剂量。</p><p> Pooling results from trials in the United Kingdom and another in Brazil, the researchers found the two-full-dose regimen was 62 percent effective at preventing COVID-19—a good, but not great result. The half-dose/full-dose regimen, on the other hand, appeared 90 percent effective—a rather impressive result.</p><p> 研究人员汇总了英国和巴西另一项试验的结果，发现两剂全剂量方案在预防COVID-19方面有62％的有效率，这是一个很好的结果，但效果不是很好。另一方面，半剂量/全剂量方案显示出90％的有效-相当可观的结果。</p><p> The trouble is, there was never supposed to be a half-dose-full-dose regimen in any of the trials.</p><p> 麻烦的是，在任何试验中都从未设想过采用半剂量全剂量方案。</p><p>  “The reason we had the half-dose is serendipity,” Mene Pangalos, AstraZeneca’s head of non-oncology research and development,  told Reuters in an interview Monday.</p><p>  阿斯利康非肿瘤研究与开发负责人梅内·潘加洛斯（Mene Pangalos）周一在接受路透社采访时说：“我们服用半剂量药物的原因是偶然性。”</p><p> Pangalos explained that when the UK trial first began, Oxford researchers were giving patients their first round of shots and noticed that the vaccine’s side-effects—fatigue, headache, arm aches—were milder than expected.</p><p> 潘加洛斯解释说，当英国试验首次开始时，牛津大学的研究人员正在给患者进行第一轮注射，并注意到该疫苗的副作用（疲劳，头痛，手臂疼痛）比预期的要温和。</p><p> “So, we went back and checked ... and we found out that they had underpredicted the dose of the vaccine by half,” Pangalos said. The researchers then decided to continue on with the trial and give the relatively small number of incorrectly dosed patients the proper dose for their second shot.</p><p> 潘加洛斯说：“所以，我们回去检查了……我们发现他们将疫苗的剂量低估了一半。”然后，研究人员决定继续进行试验，并为相对少量的剂量错误的患者提供第二次注射的适当剂量。</p><p> In the pooled trial analysis, 2,741 participants were recruited while the incorrect half-dose/full-dose regimen was used and 8,895 participants were involved in the analysis of the two-full-dose regimen.</p><p>在汇总试验分析中，招募了2,741名参与者，同时使用了不正确的半剂量/全剂量方案，并且有8,895名参与者参与了两次全剂量方案的分析。</p><p> AstraZeneca and Oxford have been mum about how that error occurred exactly. Meanwhile, outside experts have raised doubt about whether the 90 percent efficacy with the half-dose/full-dose is even real, given the smaller number of participants.</p><p> 阿斯利康和牛津一直对这个错误的确切发生方式持沉默态度。同时，外界专家对半剂量/全剂量的90％疗效是否真实存在提出了疑问，因为参与者人数较少。</p><p>    Another wrinkle is that the dosing error occurred early in the trial when researchers were only recruiting people between the ages of 18 and 55—excluding older people more vulnerable to disease. The analysis with the two-full doses, on the other hand, did include older age groups.</p><p>    另一个问题是，剂量错误发生在试验的早期，当时研究人员只在招募18至55岁之间的人，而较易患疾病的老年人除外。另一方面，两次全剂量的分析确实包括了老年组。</p><p>  “There are a number of variables that we need to understand and what has been the role of each one of them in achieving the difference in efficacy,” Moncef Slaoui, chief scientist of the US government’s Operation Warp Speed, said in a press briefing Tuesday.</p><p>  “我们需要了解许多变量，并且每个变量在实现功效差异方面起着什么作用，”美国政府“经编速度”行动首席科学家蒙西夫·斯劳伊（Moncef Slaoui）在周二的新闻发布会上说。</p><p> Operation Warp Speed has invested in AZD1222 and is supporting an ongoing trial of the vaccine in the US. Slaoui noted in the press conference that they knew about the dosing error at the time it happened. “When they realized that there was an error—or a change in the approach, the technique used—they corrected it,” he said.</p><p> Warp Speed行动已投资AZD1222，并正在美国进行该疫苗的正在进行的试验。 Slaoui在新闻发布会上指出，他们知道剂量错误发生的时间。他说：“当他们意识到存在错误-或方法改变时，所使用的技术-便对其进行了纠正。”</p><p> Now that the results have come out, Slaoui says it’s important to dig into what was going on between the two regimens. For one thing, researchers should look to see if there are  different immune responses induced by the different dosages schemes. Some researchers have speculated that ramping up the vaccine dosage between the first and second shot could have helped build up better immune responses against the pandemic coronavirus, SARS-CoV-2.</p><p> 既然结果已经出来，斯劳伊说，重要的是要深入研究两种治疗方案之间的情况。一方面，研究人员应该看看是否有不同剂量方案引起的不同免疫反应。一些研究人员推测，在第一次和第二次注射之间增加疫苗剂量可能有助于建立针对大流行性冠状病毒SARS-CoV-2的更好的免疫反应。</p><p> Others have speculated that starting with a strong dose—as in the two-full-dose regimen— may have foiled efficacy because of the way AZD1222 is designed. The vaccine uses a weakened adenovirus as packaging to deliver to the immune system the genetic code for the SARS-CoV-2 spike protein. But starting out with a strong first dose may prime the immune system to focus on attacking the adenovirus, rather than the packaged coronavirus component, some think.</p><p> 其他人推测，由于采用AZD1222的设计方式，从大剂量开始（如在两次全剂量方案中）可能会挫败疗效。该疫苗使用弱化的腺病毒作为包装，将SARS-CoV-2刺突蛋白的遗传密码传递至免疫系统。但有人认为，从高剂量的第一剂开始可能会使免疫系统专注于攻击腺病毒，而不是包装的冠状病毒成分。</p><p> Once researchers have a better understanding of what was going on, then they can make decisions about altering the ongoing trials, Slaoui said. In the US, about 11,000 of a planned 40,000 participants have been recruited for a Phase III trial of AZD1222. So, it could still be altered to include the half-dose regimen if new information comes in. However, Salaoui noted that such information would have to come quickly, given the rate the pandemic is progressing in the US.</p><p>一旦研究人员对所发生的事情有了更好的了解，他们就可以做出改变正在进行的试验的决定。在美国，已计划招募的40,000名参与者中的大约11,000名已被招募到AZD1222的III期试验。因此，如果有新信息出现，仍可以更改为包括半剂量治疗方案。但是，萨拉乌伊（Salaoui）指出，鉴于大流行在美国的发展速度，此类信息必须尽快提供。</p><p> On a final note, Slaoui reemphasized that the difference in efficacy and the dosage error as whole could be meaningless in the end: “The 90 percent efficacy group and the 62 percent efficacy group are overlapping statistically, so it is still possible that that difference is a random difference,” he said. “It’s unlikely but it’s still possible it’s a random difference.”</p><p> 最后，Slaoui再次强调功效和剂量误差的差异最终可能毫无意义：“ 90％功效组和62％功效组在统计上是重叠的，因此仍然有可能存在差异他说。 “这不太可能，但仍有可能是随机的差异。”</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2020/11/astrazenecas-best-covid-vaccine-result-was-a-fluke-experts-have-questions/">https://arstechnica.com/science/2020/11/astrazenecas-best-covid-vaccine-result-was-a-fluke-experts-have-questions/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/covid/">#covid</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>